Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Wilczak N;Wilczak N; de Vos RA; De Keyser J
  • المصدر:
    Lancet (London, England) [Lancet] 2003 Mar 22; Vol. 361 (9362), pp. 1007-11.
  • نوع النشر :
    Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Print ISSN: 0140-6736 (Print) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
    • بيانات النشر:
      Publication: 2004- : London : Elsevier
      Original Publication: London : J. Onwhyn
    • الموضوع:
      Amyotrophic Lateral Sclerosis/*metabolism ; Insulin-Like Growth Factor Binding Protein 2/*metabolism ; Insulin-Like Growth Factor Binding Protein 5/*metabolism ; Insulin-Like Growth Factor Binding Protein 6/*metabolism ; Insulin-Like Growth Factor I/*metabolism ; Motor Neurons/*metabolism ; Receptor, IGF Type 1/*metabolism; Aged ; Aged, 80 and over ; Case-Control Studies ; Female ; Humans ; Insulin-Like Growth Factor Binding Protein 2/physiology ; Insulin-Like Growth Factor Binding Protein 5/physiology ; Insulin-Like Growth Factor Binding Protein 6/physiology ; Male ; Middle Aged
    • نبذة مختصرة :
      Background: Insulin-like growth factor-I (IGF-I) is a potent survival factor for motor neurons and is being investigated as possible therapeutic agent for amyotrophic lateral sclerosis. However, very little information is available on the components of the IGF-I system in this disease. Insulin-like growth factor binding proteins (IGFBPs) play an important part in regulating the bioavailability of IGF-I.
      Methods: We investigated the components of the IGF-I system in spinal cord sections of ten patients with amyotrophic lateral sclerosis and in ten controls without neurological disease. IGF-I was studied by western immunoblotting. IGFBPs and IGF-I receptors were investigated by immunohistochemistry and Western immunoblotting.
      Findings: Total IGF-I in ventral horn homogenates did not differ between patients and controls. However, free IGF-I was 53% lower in patients than in controls. Compared with controls, immunoreactivity in the spinal motor neurons of patients with amyotrophic lateral sclerosis was 64% higher for IGFBP2, 46% higher for IGFBP5, and 33% higher for IGFBP6, with upregulation of IGF-I receptors. Immunoreactivity for IGFBPs1, 3, and 4 did not differ between patients and controls.
      Interpretation: In the ventral horns of patients, free IGF-I is reduced, which could be because of specific increases in IGFBPs 2, 5, and 6 in spinal motor neurons. This abnormality might have an important role in the processes leading to motor neuron death, and should be taken into account when developing treatments aimed to stimulate IGF-I receptors in motor neurons.
    • الرقم المعرف:
      0 (Insulin-Like Growth Factor Binding Protein 2)
      0 (Insulin-Like Growth Factor Binding Protein 5)
      0 (Insulin-Like Growth Factor Binding Protein 6)
      67763-96-6 (Insulin-Like Growth Factor I)
      EC 2.7.10.1 (Receptor, IGF Type 1)
    • الموضوع:
      Date Created: 20030328 Date Completed: 20030408 Latest Revision: 20220309
    • الموضوع:
      20250114
    • الرقم المعرف:
      10.1016/S0140-6736(03)12828-0
    • الرقم المعرف:
      12660059